Teva Pharmaceutical Industries Ltd (TEVA) stock
Close on Nov 10, 2026Market cap $49.41BP/E 70.7Yield –
Teva Pharmaceutical Industries Ltd saw revenue fall 15.2% to $14.10B over the twelve months to Jun 30, 2026. Operating income rose 79.3% to $1.60B, moving the operating margin from 5.4% to 11.4%. Free cash flow was $1.35B, up 51.5% from a year earlier. At the latest close the market valued the company at $49.41B, 70.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $49.41B
- P/E ratio
- 70.7
- Price to sales
- 3.50
- Price to book
- 6.37
- Dividend yield
- –
- Free cash flow yield
- 2.73%
Fundamentals
- Revenue
- $14.10B
- Net income
- $706.00M
- EPS, diluted
- $0.60
- Free cash flow
- $1.35B
- Book value per share
- $6.65
- Diluted shares
- 1.17B
Trading
- Next earnings
- Jan 11, 2027 (estimated, before the open)
- Previous close
- $42.97
- Open
- $42.46
- Day's range
- $41.64 – $42.69
- Volume
- 6,223,960
- Average volume (20 days)
- 7,011,837
- Beta (5 years)
- 0.98
- 52-week range
- $23.98 – $43.34
- RSI (14 days)
- 59.8
- Volatility (1 year)
- 33.9%
- Relative volume
- 1.07×
- WACC
- 9.5%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | TEVA | S&P 500 | Difference | TEVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.2% | -3.7% | +6.8 pts | ||
| 3 months | +17.3% | -2.7% | +20.1 pts | ||
| Year to date | +35.9% | +10.8% | +25.0 pts | ||
| 1 year | +74.8% | +11.2% | +63.5 pts | ||
| 3 years | +388.5% | +76.5% | +312.0 pts | +69.7% | +20.8% |
| 5 years | +351.1% | +72.9% | +278.1 pts | +35.2% | +11.6% |
| 10 years | +10.4% | +304.8% | −294.4 pts | +1.0% | +15.0% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Teva Pharmaceutical Industries filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- Results
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined ExecutionResults
- Results
About Teva Pharmaceutical Industries
Pharmaceutical Preparations
Teva Pharmaceutical Industries is a global biopharmaceutical enterprise that develops, manufactures, and commercializes generic pharmaceuticals, biosimilars, innovative therapies, and over-the-counter healthcare products. Its commercial operations are organized into three primary geographic segments: the United States, Europe, and International Markets, supplemented by auxiliary operations in active pharmaceutical ingredient manufacturing, contract production, and product out-licensing. The company targets core therapeutic areas including central nervous system conditions, respiratory illnesses, and oncology. Teva provides medicines to diverse healthcare and commercial clients, including wholesale distributors, retail drug chains, independent pharmacies, mail-order distributors, hospitals, and physician practices.
Company profile, executives and historyTeva Pharmaceutical Industries stock: common questions
What is Teva Pharmaceutical Industries's stock price?
TEVA closed at $42.40 on Nov 10, 2026, down 1.33% on the day. Over the past 52 weeks it traded between $23.98 and $43.34.
What is Teva Pharmaceutical Industries's market cap?
Teva Pharmaceutical Industries was worth $49.41B at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is TEVA's P/E ratio?
TEVA trades at 70.7 times earnings, based on diluted earnings per share of $0.60 over the twelve months to Jun 30, 2026.
How much revenue does Teva Pharmaceutical Industries make?
Teva Pharmaceutical Industries reported revenue of $14.10B for the twelve months to Jun 30, 2026, down 15.2% from a year earlier.
Does Teva Pharmaceutical Industries pay a dividend?
No. Teva Pharmaceutical Industries has not paid a cash dividend over the last twelve months.
When does Teva Pharmaceutical Industries report earnings next?
Teva Pharmaceutical Industries is expected to report Q4 FY2026 results on Jan 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TEVA stock performed over the past year?
Including dividends, TEVA returned +74.8% over the past year, against +11.2% for the S&P 500.
How many TEVA shares are sold short?
28M shares were sold short at the latest FINRA report, 2.39% of the float, or 5.3 days of average trading volume.
Who are Teva Pharmaceutical Industries's competitors?
Companies most similar to Teva Pharmaceutical Industries by business, industry and size include VTRS, GRFS, BHC, REGN, AMRX.
See a number that looks wrong?